Dr. Anton Yuryev discovered proteins physically linking gene transcription and mRNA processing in eukaryotic cells during Johns Hopkins University graduate program in 1995. He worked over 30 years in bioinformatics as Senior Scientist at InforMax, Senior Bioinformatics Analyst at Orchid Cellmark, and Application Science Director at Ariadne Genomics founded by him in 2003. Dr. Yuryev has published over 50 scientific articles, edited four books, algorithms for primer design, pathway and network analysis. After Ariadne Genomics acquisition by Elsevier Dr. Yuryev works as a Professional Services Director at Elsevier. He develops dedicated bioinformatics solutions using Elsevier software, knowledgebases and artificial intelligence in areas of drug development, personalized medicine, agro- and synthetic biology. Dr. Yuryev’s interests involve statistical modeling for drug repurposing, drug target prioritization, and therapy optimization for individual patients utilizing knowledge about molecular mechanisms of all human malignancies including rare diseases and cancers extracted from scientific literature.
Dr. Yuryev introduces Elsevier biomedical knowledge graph and its applications for per-sonalized medicine. Dr. Castillos describes how Elsevier technology is integrated at WakeMed, including clinical paths, payment options, success rates based on five-year ex-perience in using affordable personalized drug therapy selection for advanced cancer pa-tients.